Shandong Sanyuan Biotechnology Co.,Ltd. Stock

Equities

301206

CNE100005774

Food Processing

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-23 pm EDT 5-day change 1st Jan Change
28.25 CNY +0.89% Intraday chart for Shandong Sanyuan Biotechnology Co.,Ltd. -3.02% -2.18%
Sales 2024 * 770M 106M Sales 2025 * 881M 122M Capitalization 5.72B 789M
Net income 2024 * 125M 17.26M Net income 2025 * 162M 22.37M EV / Sales 2024 * 7.42 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 6.49 x
P/E ratio 2024 *
45.6 x
P/E ratio 2025 *
35.3 x
Employees 427
Yield 2024 *
1.1%
Yield 2025 *
1.42%
Free-Float 31.78%
More Fundamentals * Assessed data
Dynamic Chart
Shandong Sanyuan Biotechnology Co.,Ltd. Announces Final Cash Dividend on A Shares for 2023, Payable on 29 May 2024 CI
Shandong Sanyuan Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Certain A Shares of Shandong Sanyuan Biotechnology Co.,Ltd. are subject to a Lock-Up Agreement Ending on 10-FEB-2024. CI
EU Opens Anti-Dumping Probe Into Sanyuan Biotechnology’s Erythritol Products MT
Shandong Sanyuan Biotechnology Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Sanyuan Biotechnology Co.,Ltd.(XSEC:301206) added to S&P Global BMI Index CI
Shandong Sanyuan Biotechnology Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shandong Sanyuan Biotechnology Co.,Ltd. Implements Final Profit Distribution Plan (A Shares) for 2022, Payable on 21 June 2023 CI
Shandong Sanyuan Biotechnology Co.,Ltd. Approves Cash Dividend for the Year 2022 CI
Shandong Sanyuan Biotechnology Co.,Ltd. Proposal Final Cash Dividend for 2022 CI
Shandong Sanyuan Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shandong Sanyuan Biotechnology Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hapioneer announced that it has received $8.200000 million in funding from Shandong Sanyuan Biotechnology Co.,Ltd. and other investors. CI
Shandong Peixue Bioengineering Co., Ltd. announced that it expects to receive CNY 60 million in funding from Shandong Sanyuan Biotechnology Co.,Ltd. CI
More news
1 day+0.89%
1 week-3.02%
Current month-0.25%
1 month+8.53%
3 months+13.09%
6 months-5.77%
Current year-2.18%
More quotes
1 week
27.90
Extreme 27.9
29.45
1 month
26.10
Extreme 26.1
35.89
Current year
20.80
Extreme 20.8
35.89
1 year
20.80
Extreme 20.8
37.42
3 years
20.80
Extreme 20.8
97.33
5 years
20.80
Extreme 20.8
97.33
10 years
20.80
Extreme 20.8
97.33
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 11-10-31
Director of Finance/CFO 53 19-06-30
Chairman 73 06-12-31
Members of the board TitleAgeSince
Chairman 73 06-12-31
Director/Board Member 72 10-03-31
Director/Board Member 37 09-08-31
More insiders
Date Price Change Volume
24-05-24 28.25 +0.89% 1,337,100
24-05-23 28 -3.08% 1,559,750
24-05-22 28.89 -0.52% 1,452,100
24-05-21 29.04 -0.41% 1,536,150
24-05-20 29.16 +0.10% 2,111,450

End-of-day quote Shenzhen S.E., May 23, 2024

More quotes
Shandong Sanyuan Biotechnology Co Ltd is a China-based company mainly engaged in the production and sales of new sweetener products. The Company's main products are erythritol and compound sugar. The compound sugar products include momordica grosvenori compound sugar, stevia compound sugar, sucralose compound sugar and others. The Company's products are sold to America, Europe, Africa, Oceania and other regions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
28.25 CNY
Average target price
32 CNY
Spread / Average Target
+13.27%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 301206 Stock